Ankylosing Spondylitis - Epidemiology Forecast to 2022
Category : Pharma & Healthcare
All logos and Images mentioned on this slide belong to their respective owners.
Introduction to Report
Launch Date: March 27, 2014
Number of Pages: 49
Geography Coverage: Global
Available Format: PDF
Price For Single User License: USD 3,995
Price For Site User License: USD 7,990
Price For Global User License: USD 11,985
Delivery Time: Within 24 Hours (During Working Days)
About the Report
Ankylosing spondylitis is a systemic, chronic, and
progressive inflammatory arthritis in the family of
seronegativespondyloarthritis, and is one of the most
common rheumatic conditions throughout the world.
Ankylosing spondylitis primarily affects the spine and
sacroiliac joints, with involvement with other joints in the
shoulders, hips, and knees. It can progress into severe
inflammation that fuses the spine, leading to permanent
painful stiffness of the back.
Although treatment helps in relieving pain and stiffness
and keeps the spine flexible, the disease is irreversible
and people with the disorder have to cope with
symptoms throughout their lives. Global prevalence of
the disease ranges from 0.01%–1.40%, with higher
prevalence in western European Caucasian populations.
Publisher epidemiologists forecast an increase in the diagnosed
prevalent cases of ankylosing spondylitis in the 7MM, from
818,456 diagnosed prevalent cases in 2012 to 850,849 diagnosed
prevalent cases in 2022, with an annual growth rate (AGR) of
0.40%. Throughout the forecast period, the US will have the
highest number of diagnosed prevalent cases of ankylosing
spondylitis, with 608,813 diagnosed prevalent cases in 2022.
This forecast provides detailed and clinically relevant
segmentations of ankylosing spondylitis prevalent cases in the
7MM. These segmentations allow for an improved
understanding of the disease epidemiology and the ability to
focus on specific subgroups. Trends in the diagnosed prevalent
cases of ankylosing spondylitis are a direct result of changing
population demographics in the 7MM.
The analysis is strengthened by the use of sources with
validated diagnostic criteria and uniform methodology in each
market, allowing for a meaningful comparison of the diagnosed
prevalent cases of ankylosing spondylitis across the 7MM.
The Ankylosing Spondylitis EpiCast Report provides an
overview of the risk factors, comorbidities, and global
trends ofankylosing spondylitis in the seven major
markets (7MM) (US, France, Germany, Italy, Spain, UK,
and Japan).It includes a 10-year epidemiological forecast
for the diagnosed prevalent cases of ankylosing
spondylitissegmented by age (beginning at 15 years and
ending at 65 years and older), sex, and HLA-B27
seropositivitystatus in these markets.
The ankylosing spondylitisepidemiology report is written
and developed by Mastersand PhD-level epidemiologists.
The EpiCast Report is in-depth, high quality, transparent
and market-driven, providing expert analysis of disease
trends in the 7MM.
Reasons To Buy
Develop business strategies by understanding the trends
shaping and driving the global ankylosing
Quantify patient populations in the globalankylosing
spondylitismarket to improve product design, pricing, and
Organize sales and marketing efforts by identifying the
sex and age groupsthat present the best opportunities for
ankylosing spondylitistherapeutics in each of the markets
Table of Contents
Are you an industry professional, entrepreneur,
venture capitalist, investors and organization, then let
us know your specific research requirements. Our goal
is to cater to your requirements be it for a custom
market research project, syndicated research report on
a specific market or industry sector, newsletter creation,
case study development or anything else related to
For Any Customization Related query Visit IdeaCenter @
How To Buy This Report?
Visit following URL to see Table of Content and
purchase this publication:
About Market Research Reports, Inc.
Market Research Reports provides a customized set
of reports from reputed Publishers, built on the
intelligence available within organizations and
leverages on our motto of “Intelligence Redefined”.
Contact : Amitava Sen
Email : firstname.lastname@example.org
Phone: +1 302-703-7787 (USA) +91-8762746600 (India)